Aspirin and other nonsteroidal anti-inflammatory drugs that inhibit COX-1 induce unique nonallergic reactions, consisting of attacks of rhinitis and asthma. These hypersensitivity reactions occur in a subset of asthmatic subjects, thus identifying them as having this exclusive clinical presentation. We refer to these patients as having aspirin-exacerbated respiratory disease, a disease process that produces devastating eosinophilic inflammation of both the upper and lower respiratory tracts. This review focuses on a description of patients with aspirin-exacerbated respiratory disease, methods available to diagnose their condition, the unique ability of all nonsteroidal anti-inflammatory drugs that inhibit COX-1 to cross-react with aspirin, an update on pathogenesis, and current thoughts about treatment. (J Allergy Clin Immunol 2006;118:773-86.)

Key words: Aspirin, nonsteroidal anti-inflammatory drugs, asthma, nasal polyps, chronic hyperplastic eosinophilic sinusitis, aspirin-exacerbated respiratory disease, aspirin desensitization

In 1922, Widal et al published the first article describing the association of aspirin sensitivity, asthma, and nasal polypsis. They also conducted the first aspirin challenges and desensitization. This syndrome was not widely recognized, however, until Samter published 2 articles in the late 1960s and called the condition Samter’s triad (asthma, nasal polyps, and aspirin reactions). Most clinical investigators now include chronic hyperplastic eosinophilic sinusitis (CHES) as a fourth hallmark of aspirin-exacerbated respiratory disease (AERD).

Many other terms have been used to describe this respiratory disease: aspirin-induced asthma, aspirin-sensitive asthma, aspirin hypersensitivity, aspirin idiosyncrasy, and aspirin intolerance. All terms refer to the same patients who are afflicted with intractable inflammation in both the upper and lower respiratory tracts (nasal polyps, CHES, and asthma). Exposure to aspirin does not initiate or even perpetuate the underlying inflammatory disease. However, once the disease is ongoing, aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) induce release or synthesis of critical mediators, which then cause all of the clinical manifestations of the characteristic respiratory reactions. The recent consensus nomenclature to describe aspirin-induced respiratory reactions is nonallergic hypersensitivity reactions.

PREVALENCE

Identifying the exact prevalence of AERD is difficult. Many patients have the disease but do not know it because...
they have not ingested aspirin and other NSAIDs (usually acetaminophen users). Alternatively, they experienced mild asthma attacks after ingesting NSAIDs but did not correlate these events. In a large survey of pharmacy-reported reactions to analgesics in asthmatic subjects, the prevalence of AERD was listed as 3% in adults and 2% in children. In large population surveys, using questionnaires to ask about asthma and aspirin inducing shortness of breath or asthma attacks, the prevalence was 1.2% (sample size, 4300), but the incidence of aspirin sensitivity was much higher in patients whose physician made a diagnosis of asthma (8.8%). In a large population survey in Poland (12,971 adults), 4.3% of asthmatic subjects identified themselves as reacting to aspirin with asthmatic attacks. In Perth, Australia, in a survey of 516 asthmatic patients and 1298 randomly selected individuals, the prevalence was reported to be 11% among asthmatic subjects and 2.5% among the general population.

Investigators have performed prospective oral aspirin challenges on various populations of asthmatic patients to circumvent the problem of prior nonexposure to aspirin/NSAIDs in asthmatic patients. During such aspirin challenge studies in adult asthmatic subjects, the incidence of AERD has ranged from 10% to 20% in the pre-1990 literature. In a meta-analysis of 15 studies performed after 1990 using oral aspirin challenges to detect aspirin hypersensitivity in asthmatic populations, the combined prevalence was 21% (CI, 14% to 29%), whereas in 5 studies in children (0-18 years) the combined prevalence was only 5% (CI, 0% to 14%).

When target populations of asthmatic subjects are further stratified and include only those who also had nasal polyps and chronic sinusitis, the prevalence of aspirin hypersensitivity, discovered by means of prospective oral aspirin challenges, was found to be even higher, in the range of 30% to 40%. In fact, the one study in children that stands out as having a high incidence of positive oral aspirin challenge results was actually in a population of teenagers who had nasal polyps, chronic sinusitis, severe asthma, and a high prevalence of steroid dependency. Teenagers are probably more like adults than prepubertal children with respect to being vulnerable to acquiring AERD. The general experience is that aspirin/NSAID hypersensitivity in preschool asthmatic subjects is incredibly rare.

Asthmatic patients who reported a history of aspirin- or NSAID-induced asthma attacks (i.e., believed they were “aspirin sensitive”) experienced positive oral aspirin challenges of 66%, 84%, and 97% of the time in these 3 studies. These observations point out the problem of overdiagnosing AERD when relying on a history of asthma after ingestion of aspirin or NSAIDs. In some patients a coincidence occurred in that aspirin or an NSAID was ingested within 3 hours of the asthma attack, but the 2 events were unrelated to each other. The best histories include ingestion of a therapeutic dose of any NSAID that preferentially inhibits COX-1, followed by a severe asthma attack requiring emergency intervention, an NSAID-associated asthma attack at another time, or both.

### Natural History and Clinical Presentation of AERD

Consistent with a low prevalence of AERD in preteenagers, AERD is an acquired disorder with an onset of symptoms beginning somewhere between the teenage years and age 40 years. The average ages of onset were 34 and 29 years in 2 large studies involving 300 and 500 patients with AERD, respectively. There are more female than male subjects who acquire this disease: in a study of 300 patients from the United States, a 3:2 ratio of female/male sex was found, whereas in Europe a 2.3:1 ratio was found. There is no racial or ethnic predilection for acquiring AERD. Family histories of AERD are rare and reported in 6% of patients in the European survey but in only 1% of patients in the US series.

Aspirin hypersensitivity can appear in patients who already have allergic rhinitis and allergic asthma or any other provoking factor for their asthma (e.g., gastroesophageal reflux disease, viral respiratory tract infections, irritant inhalation, or exercise) or it can appear in patients who already have never had any prior respiratory disease. In a review of 103 German and Polish patients with AERD, 34% had positive skin prick test responses to at least one aeroallergen. In the United States series of 300 patients with AERD, the prevalence of positive wheal-and-flare skin test responses was 64% but included both prick and intradermal testing.

The first clinical manifestation of AERD is usually nasal congestion, but it might be superimposed on patients who already have allergic rhinitis. Many patients remember an upper respiratory tract viral infection as the inciting event (“My cold never went away”). In 1988, Szczeklik presented a theory that a viral respiratory tract infection might be an inciting event that starts the inflammatory cascade, leading to AERD in genetically susceptible individuals. Another idea is that diesel exhaust and cigarette smoke exposure, both of which contain polyaromatic hydrocarbons, such as benzopyrene and phenanthrene, stimulate respiratory epithelial cells to synthesize cytokines (IL-1, IL-6, IL-16, and GM-CSF), which drives a TH2 response.

In an epidemiologic study a significantly higher prevalence of exposure to passive cigarette smoke during childhood and young adult life was found in patients with AERD when compared with their asymptomatic spouses, acting as control subjects (unpublished data, J. Martin and D. D. Stevenson). Hyposmia or anosmia occurs in most patients with AERD. In fact, normal olfaction correlates with not having AERD.

In AERD the original chronic rhinitis progresses to CHES with nasal polypsis. Computed tomography or plain radiography of the sinuses revealed opacifications in 99% of patients in one study. In this same study 94% of patients with AERD had undergone at least 1 and averaged 3 prior sinus and polyp operations.

Asthma was either previously present in childhood and young adult life (usually IgE mediated) or begins de novo between 3 months and up to 5 years (average, 2 years) after onset of nasal congestion and polypsis.
NSAID-induced hypersensitivity respiratory reactions can appear at any time in the course of the disease, but until such an event occurs, the diagnosis of AERD cannot be considered. Despite avoidance of aspirin and NSAIDs, mucosal inflammation of the upper and lower respiratory tracts persists and progresses. This strongly supports the fact that ingestion of aspirin and the older NSAIDs exacerbate an inflammatory condition that is already active, rather than being responsible for inducing the disease in the first place.

RESPIRATORY REACTIONS TO ASPIRIN AND NSAIDs

Cross-reactions among the NSAIDs that inhibit COX-1

Patients with AERD react to aspirin, as well as all older NSAIDs that preferentially inhibit COX-1 (Table I), inducing a spectrum of respiratory reactions, including rhinitis and conjunctivitis, laryngeal spasm, and asthma attacks. The reactions usually occur within 30 to 60 minutes after ingesting full therapeutic doses of aspirin or NSAIDs but can occur up to 3 hours later, particularly when patients are challenged with smaller aspirin doses in the range of 30 to 100 mg. Assuming that the doses of NSAIDs are in the therapeutic range, cross-reactivity among NSAIDs that inhibit COX-1 is 100% (Table I).

In a study of 300 patients in the United States with documented AERD, aspirin was the most commonly reported NSAID (80%) to elicit prior respiratory reactions, followed by ibuprofen (41%). Of the 300 patients, 36% experienced 3 or more previous respiratory reactions to aspirin and NSAIDs, indicating that a third of patients had a significant delay in diagnosis. This suggested either observational confusion on the part of the patients and their physicians or insufficient education by health care providers regarding avoidance strategies.

Partial cross-reactivity with poor inhibitors of COX-1

Salsalate and acetaminophen are poor inhibitors of COX-1 (Table I). However, at high doses, both can induce mild respiratory reactions in patients with AERD. Most patients with AERD can safely tolerate up to 500 mg of acetaminophen, but 28% experienced mild respiratory reactions to 1000 mg of acetaminophen, and another 6% reacted when doses were increased to 1500 mg. Patients with AERD can take salsalate in doses of less than 2000 mg. However, when 2000 mg was given to patients with AERD, mild respiratory reactions occurred in 10% of patients undergoing oral challenges with salsalate. When reactions are elicited at higher doses of acetaminophen and salsalate, they tend to be milder than those observed with the older NSAIDs.

Partial cross-reactivity with partially selective COX-2 inhibitors

Meloxicam and nimesulide (Table I) are 2 anti-inflammatory drugs that preferentially inhibit COX-2 at lower concentrations but inhibit COX-1 at higher therapeutic concentrations (ie, 15 mg of meloxicam). Similar to salsalate and acetaminophen, respiratory reactions can occur with higher doses of these 2 drugs and tend to be relatively mild. Only meloxicam is available in the United States, but both are available worldwide.

Unusual cross-reactivity with selective COX-2 inhibitors

Selective COX-2 inhibitors, such as rofecoxib, celecoxib, valdecoxib, etoricoxib, parecoxib, and lumiracoxib, are the most recent category of NSAIDs to enter and, for some, to then exit the market (Table III). Many clinicians are apprehensive about prescribing selective COX-2 inhibitors to patients with AERD because warning labels on all coxibs list “aspirin triad” as a contraindication for prescribing these drugs. Since 2001, well-designed studies, however, demonstrated that selective COX-2 inhibitors, given in therapeutic dosages, have not cross-reacted with aspirin or NSAIDs in any patients with AERD participating in these studies.

In a double-blind placebo-controlled trial, Stevenson and Simon challenged 60 patients with AERD with rofecoxib. None of the patients reacted after ingesting 12.5 mg and 25 mg of rofecoxib. Martin-Garcia et al and Szczeklik et al conducted single-blind challenges in a total of 52 more patients with AERD with up to 25 mg of rofecoxib, and none reacted. Woessner challenged 60 patients with AERD with even higher doses of rofecoxib (50 mg or 2 times the therapeutic dose), and again, none of the patients had any adverse reactions. Rofecoxib has been withdrawn from the market.

Celecoxib has also been studied in patients with AERD. Yoshida et al challenged 17 patients with AERD with 200 mg of celecoxib, and none reacted. Woessner et al

---

TABLE I. Universal cross-reactions between aspirin and non-NSAIDs occur

<table>
<thead>
<tr>
<th>NSAID</th>
<th>Concentration</th>
<th>Cross-reactivity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen</td>
<td>1000 mg</td>
<td>30% to 100%</td>
</tr>
<tr>
<td>Acetaminophen</td>
<td>2000 mg</td>
<td>100%</td>
</tr>
<tr>
<td>Meloxicam</td>
<td>15 mg</td>
<td>100%</td>
</tr>
<tr>
<td>Rofecoxib</td>
<td>12.5 mg</td>
<td>100%</td>
</tr>
<tr>
<td>Celecoxib</td>
<td>50 mg</td>
<td>100%</td>
</tr>
</tbody>
</table>

*Generic name (brand names).*
conducted double-blind placebo-controlled challenges in which 60 patients with AERD were given 200 mg of celecoxib, and none of the patients reacted. Gyllfors et al. challenged 32 patients with AERD with 400 mg of celecoxib, and again, none of the patients reacted. Furthermore, there was no increase in urinary leukotriene E4 (uLTE4) levels during celecoxib challenges, but the usual increase in uLTE4 levels occurred when the same patients were challenged with aspirin. Valdecoxib is also a COX-2 inhibitor that entered and then exited the US market. Woesner completed a double-blind placebo-controlled study of 70 patients with proved AERD. None of the patients had adverse reactions to 20 mg of valdecoxib. Etoricoxib is another highly selective COX-2 inhibitor and is available by prescription outside the United States. By experience, it has been well tolerated by patients with AERD. In a recent report from Italy, 27 subjects with mostly urticarial and angioedema reactions to NSAIDs, only 3 of whom had AERD, underwent challenges with a new selective COX-2 inhibitor, parecoxib. None reacted to parecoxib, which is the first injectable coxib. Lumiracoxib is another coxib available outside the United States. We did not find case reports of respiratory reactions to lumiracoxib.

However, a word of caution; despite all of the safety data and lack of cross-reactivity for use of selective COX-2 inhibitors in large numbers of patients with AERD, rare case reports of respiratory reactions to selective COX-2 inhibitors have appeared in the literature. A most instructive case was reported by Baldassarre et al. They described a 45-year-old woman with AERD who experienced asthma attacks by history after paracetamol (500 mg) and by oral challenge after aspirin (10 mg) and celecoxib (15 mg). In addition, during her respiratory reaction to celecoxib, her uLTE4 level increased from a baseline value of 368 to 1318 pg/mg creatinine. Her unusual sensitivity to aspirin (10 mg) is in contrast to the average aspirin provoking dose of 60 mg (range, 30-100 mg), which is characteristic of large numbers of patients with AERD undergoing oral aspirin challenges. One of the authors of this review (AS) has recently worked with a 30-year-old woman with AERD who had very high baseline uLTE4 levels (40 times the upper limit of normal). During oral challenges, she reacted with bronchospasm after celecoxib and went into anaphylactoid shock after aspirin. Similar case reports for celecoxib, rofecoxib, and etoricoxib make it impossible to take the position that coxibs never induce respiratory reactions in patients with AERD.

It is difficult to understand the mechanisms that might account for the case reports described above. COX-2 inhibitors are designed with a side arm so that their entrance into the smaller COX-1 channel is prevented by the reduced size of the entrance and lack of a side pocket within the enzyme. Because of this feature, COX-2 inhibitors are between 5- and 50-fold more selective for COX-2 over COX-1. Therefore with very high doses of selective COX-2 inhibitors, one could envision such a high drug concentration around the mouth of the COX-1 enzymes that arachidonic acid could not enter the channel. However, low to usual therapeutic doses of COX-2 inhibitors have participated in what on the surface appear to be cross-reactions. We are not able to explain why these rare reactions occur, but genetic differences in the structure of the COX-1 channel would be interesting to investigate.

Some patients with AERD rarely experience respiratory, urticarial, and anaphylactic reactions through immune recognition of a specific COX-2 inhibitor. It is well known that COX-2 inhibitors, like any of the NSAIDs, can induce IgE-mediated reactions. In other words, patients with AERD are not protected from experiencing other types of specific immune reactions that have nothing to do with inhibition of COX-1. Whatever the mechanisms, as prescribing physicians, we can never guarantee that patients will not react to a selective COX-2 inhibitor. It seems logical to us to give the first full dose of a COX-2 inhibitor in the physician’s office to patients with AERD or asthmatic subjects with unknown sensitivities. Unfortunately, because of an increase in cardiovascular adverse events, rofecoxib and valdecoxib were withdrawn from the world market. Currently, the only remaining selective COX-2 inhibitor in the United States is celecoxib. Outside the United States, etoricoxib, parecoxib, and lumiracoxib are available (Table III).

### TABLE II. Cross-reactions with aspirin occur with higher doses of these drugs

<table>
<thead>
<tr>
<th>A. NSAIDs that are poor inhibitors of COX-1</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acetaminophen (paracetamol) (Tylenol)</td>
</tr>
<tr>
<td>Salicylate (Disalcid)</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>B. NSAIDs that preferentially inhibit COX-2 at lower doses but also inhibit COX-1 when higher doses are given</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nimesulide (Aulin, Nimesil)</td>
</tr>
<tr>
<td>Meloxicam (Mobic)</td>
</tr>
</tbody>
</table>

### TABLE III. Selective COX-2 inhibitors preferentially inhibit COX-2

<table>
<thead>
<tr>
<th>Celecoxib (Celebrex)*</th>
<th>Rofecoxib (Vioxx)†</th>
<th>Valdecoxib (Bextra)‡</th>
<th>Etoricoxib (Arcoxia)†+</th>
<th>Parecoxib (Dynastat)‡</th>
<th>Lumiracoxib (Prexige)†+</th>
</tr>
</thead>
</table>

In *vitro* studies show that in supertherapeutic concentrations of these drugs, weak inhibition of COX-1 occurs.

*Available worldwide.
†Removed from the world market in 2004 and 2005.
‡Available outside the United States.

### DIAGNOSIS OF AERD

The diagnosis of AERD can be definitively established only through provocative aspirin challenges. There is no reliable *in vitro* test, but the search for one continues. There are 4 types of provocation challenges, depending on
the route of administration and challenge drug: oral,\textsuperscript{26,59} inhalational,\textsuperscript{60-62} nasal,\textsuperscript{63-65} and intravenous.\textsuperscript{66}

In the United States oral aspirin challenges are available.\textsuperscript{67} Details for conducting these challenges can be found in a prior reference.\textsuperscript{68} Instead of starting with 30 mg of ASA during oral challenges, one can cut ASA 81 mg in half and then a quarter and start with 20.25 mg of ASA.

Patients are instructed to continue oral and topical corticosteroids, long-acting bronchodilators, cysteinyi leukotriene receptor antagonist 1 (cysLT1RA), 5-lipoxygenase inhibitor (5-LOINH), and systemic corticosteroids because discontinuing these medications can lead to an increase of hyperirritable airways. Some medications should be discontinued 24 hours before challenge, including antihistamines and short-acting inhaled \( \beta \)-agonists or anticholinergics. Antihistamines can block upper respiratory tract reactions to aspirin, which can interfere with accurate identification of patients with AERD.\textsuperscript{69} Use of short-acting \( \beta \)-agonists or anticholinergics can lead to false-positive reactions because once the short-acting bronchodilator effect has disappeared, a rapid decrease in lung function can occur. If a decrease in FEV\(_1\) is greater than 15\%, diagnostic misinterpretation might develop.\textsuperscript{68} CysLT1RA and 5-LOINH do not block upper airway reactions but do prevent or modify bronchospastic reactions during oral aspirin challenges.\textsuperscript{69,70} CysLT1RA shifts target organ responses from lower respiratory tract reactions to mostly upper respiratory tract reactions.\textsuperscript{69}

Although not available in the United States, several European centers use bronchial challenges with aspirin-lysine.\textsuperscript{62,71} Nizankowska et al\textsuperscript{62} studied the diagnostic value of bronchial inhalation challenge with L-lysine–aspirin in 35 patients with AERD who were suspected of having AERD on the basis of a prior history of NSAID reactions. Thirty-one (89\%) of 35 suspected asthmatic subjects experienced bronchospastic reactions during oral aspirin challenges. In the same patients, 27 (77\%) of 35 or, more accurately, 27 (87\%) of 31 known reactors had bronchospastic reactions during inhaled aspirin-lysine challenges.

Aspirin-lysine nasal challenges are also conducted in Europe and have a satisfactory diagnostic capability.\textsuperscript{63-65,72} In a recent study by Micheletto et al,\textsuperscript{64} both asthmatic patients with AERD and aspirin-tolerant asthmatic patients underwent nasal challenges with up to 25 mg of aspirin-lysine. Positive nasal responses and increased uLTE\(_4\) levels occurred only in the patients with AERD. Despite increased synthesis of leukotrienes (LTs), as measured in uLTE\(_4\), none of the patients with AERD experienced asthma attacks during nasal challenges, despite significant nasal responses. The major advantage of intranasal aspirin-lysine challenges is avoidance of aspirin-induced bronchospasm. The disadvantages are that pure lower respiratory tract reactors might not be identified, and in some patients with AERD, occluding nasal polyps interfere with nasal flow rates and make it impossible to perform the test.\textsuperscript{65}

In the United States a new diagnostic test for nasal challenge using a dilute solution of ketorolac has recently completed diagnostic trials.\textsuperscript{73} Ketonolac solutions (8 mg/mL), delivered as a nasal spray in increasing doses every 30 minutes, offer an alternative to aspirin-lysine nasal challenge in the United States because aspirin-lysine has not been approved for use in human subjects by the US Food and Drug Administration.

**PATHOGENESIS**

**Underlying respiratory disease (Fig 1)**

The pathophysiology of AERD has been partially elucidated. Nasal tissue biopsy specimens from patients with AERD reveal extensive infiltration of eosinophils and degranulated mast cells.\textsuperscript{74} Bronchial biopsy specimens also contain increased numbers of eosinophils and mast cells when compared with biopsy specimens from patients with aspirin-tolerant asthma.\textsuperscript{75} Why the eosinophils and activated mast cells infiltrate the respiratory mucosa in the first place is not clear and difficult to study because any prior inciting events, such as viral infections or exposure to air pollution and cigarette smoke, might have occurred years earlier. Nevertheless, once AERD appears, levels of proinflammatory cytokines synthesized by epithelial cells and activated T\(_{H2}\) lymphocytes are found to be increased. These include IL-2, IL-3, IL-4, IL-5, IL-13, GM-CSF, and eotaxin.\textsuperscript{4,76-78} The cytokines IL-3, IL-4, IL-5, IL-13, and GM-CSF all skew T-lymphocyte responses toward T\(_{H2}\), stimulate bone marrow precursor cells, recruit eosinophils, and dramatically increase the lifespan of eosinophils in vitro by inhibiting apoptosis.\textsuperscript{77} IL-5 and GM-CSF are overexpressed in inflammatory cells from mucosal biopsy specimens in patients with AERD.\textsuperscript{79} Eotaxin is also an important chemokine, the primary function of which is recruitment and activation of eosinophils, as well as contribution to tissue damage through induction of reactive oxygen radicals.\textsuperscript{80} LTC\(_4\), LTD\(_4\), and LTE\(_4\) are also chemotactic for eosinophils.\textsuperscript{81} Mast cells contain LTA\(_4\) hydrolase and therefore can covert LTA\(_4\) to LT\(_B4\), which stimulates bone marrow to form mast cell progenitors and eosinophils.\textsuperscript{82} LTC\(_4\) synthase (LTC\(_4\)S) converts LTA\(_4\) to LTC\(_4\),\textsuperscript{82} thus activating this potent pathway.\textsuperscript{83,84} The end result is a striking increase in numbers of eosinophils and mast cells in the respiratory mucosa of patients with AERD. Activated eosinophils can also release cytotoxic molecules (eg, eosinophil cationic protein, major basic protein, eosinophil-derived neurotoxin, and eosinophil peroxidase), leading to respiratory mucosal inflammation and damage.\textsuperscript{85} Despite identification of the above mechanisms, none are restricted to patients with AERD. In fact, these same inflammatory pathways and patterns can be found in non–aspirin-sensitive asthmatic subjects with nasal polyps and CHES or in allergic asthmatic subjects. There is clear evidence that most, but not all, patients with AERD synthesize excessive amounts of LTs, even before any exposure to aspirin or NSAIDs.\textsuperscript{86} Higher concentrations of LTC\(_4\) and thromboxane B\(_2\) were found in bronchoalveolar lavage fluid taken from patients with AERD compared with those seen in samples from control asthmatic subjects and healthy patients.\textsuperscript{75,87} Christie et al\textsuperscript{68}
and Smith et al were the first to measure increased levels of LTE4 in the urine of patients with AERD before aspirin challenges. Many, but not all, patients with AERD demonstrate overexpression of LTC4S in eosinophils and mast cells in their bronchial biopsy specimens, and their circulating eosinophils carry more mRNA for LTC4S. Sanak et al discovered genetic polymorphisms of the LTC4S promoter region and identified an increased prevalence of its variant type in Polish patients with aspirin-induced asthma, although the same finding also occurred in samples from some healthy individuals. Attempts to find similar patterns in more heterogeneous asthmatic subjects with AERD did not identify an increase in polymorphisms for the flanking region of the gene encoding for LTC4S. Not only is there overproduction of LTs in AERD, but Sousa et al demonstrated that in asthmatic subjects with AERD, but not in aspirin-tolerant asthmatic subjects, nasal inflammatory cells expressed more cysLT1 receptors. In patients with AERD, not only is there overproduction of LTs, but more receptors are available to receive these mediators.

Arachidonic acid is synthesized to 5-hydroxyperoxyeicosatetraenoic acid by 5-lipoxygenase (5-LO) and 5-lipoxygenase–activating protein (FLAP), with synthesis then proceeding down the LTA4 pathway or into the alternative 5-hydroxy-eicosatetraenoic acid (HETE) pathway. Leukocytes and platelets synthesize a microsomal enzyme called 5-hydroxyeicosanoid dehydrogenase, which selectively converts 5-HETE to 5-oxo-6,8,11,14-eicosatetraenoic acid (5-oxo-ETE). Respiratory stress and oxidative stress of polymorphonuclear cells activate synthesis of 5-oxo-ETE, which is a potent chemoattractant for PMNs and eosinophils. Although not specifically investigated in AERD, this proinflammatory mechanism might also be active in AERD, the extent of which is currently unknown.

Just as overproduction of cysLTs is the hallmark of AERD, underproduction of lipoxins correlates with having AERD. Lipoxins are anti-inflammatory derivatives of arachidonic acid and products of lipoxygenation. They require 2 or more lipoxygenase enzymes for biosynthesis (5-LO and 15-LO). They are generated by transcellular cooperation and are functional antagonists of LTs. Therefore diminished capacity to generate lipoxin and 15-epimer lipoxin might contribute to uncontrolled and protracted inflammation in patients with AERD. The possible relationship between this phenomenon and the accumulation of 15-HETE after stimulation with aspirin of peripheral leukocytes from patients with AERD is interesting but needs further study.
Prostaglandin (PG) D₂, a mast cell–derived prostanoid that is synthesized through the COX-1 and COX-2 pathways, is oversynthesized and secreted in asthmatic subjects with AERD. PGD₂ causes vasodilatation and bronchoconstriction. It is also a potent chemoattractant for eosinophils, operating through prostaglandin D₂ receptor [DP(2)] receptors on eosinophils. Therefore in patients with AERD, not only is there an increase in 5-LO products, but certain prostanoids are also proinflammatory and tend to be oversynthesized.

A special role for PGE₂ in the pathogenesis of AERD has been suggested. Peripheral blood macrophage cells (PBMCs) of some patients with AERD undersynthesize PGE₂ at baseline. This places patients with AERD at the disadvantage of lacking sufficient concentrations of cellular or transcellular PGE₂ to stabilize mast cells and slow synthesis of LTs. There are 4 receptors for PGE₂, E-prostanoid (EP) receptors 1 through 4. In one study single nucleotide polymorphisms (SNPs) in the promoter region of the gene encoding EP2 were significantly associated with AERD. Thus decreased transcription of the EP2 receptor for PGE₂ might render that subset of patients with AERD unable to efficiently inhibit 5-LO and FLAP, even if they synthesized normal amounts of PGE₂. Nasal mucosal biopsy specimens from patients with AERD, when immunostained for all 4 EP receptors, showed a significant reduction in numbers of neutrophils, mast cells, eosinophils, and T cells expressing EP2 receptors but not EP1, EP3, and EP4 receptors. Another study demonstrated a special role for EP3 receptors in suppressing allergic inflammation and suggested that patients with AERD might depend more on the PGE₂-EP3 receptor pathway than do aspirin-tolerant asthmatic subjects and healthy subjects. Any of these discovered defects, under synthesis of PGE₂ or its EP2 or EP3 receptors, diminishes the blocking capabilities of PGE₂ on 5-LO and FLAP or an inhibitory effect on mast cells.

Recently, several authors addressed the problem of genetic polymorphism. The most comprehensive study of genetic associations with AERD was published by Jinnai et al. Using 370 SNPs from 63 candidate genes, almost 200 patients with AERD were compared with aspirin-tolerant asthmatic subjects and control subjects. A gene coding for EP receptor 2 was the only one significantly associated with AERD. The investigators, using 24 SNPs’ haplotypes, demonstrated that a region located 11 kb upstream from the translation start of the gene had the best correlation with the AERD phenotype. A particular allele, −12 813A instead of G, in vitro had diminished transcriptional activity when stimulated by IL-4 through the IL-4 receptor–signal transducer and activator of transcription 6 pathway. This finding recaptured attention when Ying et al demonstrated that inflammatory cells infiltrating the nasal mucosa of patients with AERD were deficient in EP2.

Nearer a decade after the initial description of an association between the HLA DPB1 locus and AERD, these data were replicated by Choi et al. Despite a quite different ethnicity (Polish vs Korean), the same allele, DPB1*0301, was overrepresented in aspirin-hypersensitive asthmatic subjects. Thus an adaptive immune response to MHC class II antigens has probably occurred to mediate at least a step in the development of AERD.

Attempting to put this whole picture into perspective, many of the inflammatory pathways described above are also found in patients who have no reactions to aspirin and other NSAIDs. However, one theme that runs through most studies is that in patients with AERD, measurements of cytokines, eicosanoid mediators (uLTE₄ and PGD₂), and cysLT₁ receptors tend to group in the high end of most study results. Yet clearly separating individual asthmatic subjects with AERD from aspirin-tolerant asthmatic subjects cannot be accomplished on the basis of their inflammatory profiles, including their uLTE₄ levels, because of considerable overlap between patients with AERD and aspirin-tolerant asthmatic subjects. To make matters more difficult, patients with AERD can be mild, moderate, or severe in their clinical disease presentation and their inflammatory profiles. Despite these comments, a pattern is emerging in which many defects in either overstimulation of inflammation or underproduction of countermeasures, especially in the eicosanoid family, is found in patients with AERD. Furthermore, a single genetic defect or promoter gene that accounts for all patients with AERD has not been discovered. Rather, some patients with AERD are upregulating LTC₄S, others are upregulating cysLT₁ receptors, and still others are oversynthesizing specific cytokines. At the opposite end of the equation, some patients with AERD are undersynthesizing lipoxins, PGE₂, or EP2 or EP3 receptors. These facts would fit a theory in which multiple divergences in inflammatory pathways could occur in different patients with AERD, yet rendering all patients vulnerable to aspirin.

Aspirin- and NSAID-induced hypersensitivity reactions (Fig 2)

In patients with AERD, acute respiratory reactions induced by aspirin or NSAIDs encompass all the features of immediate IgE-mediated hypersensitivity reactions, yet such a mechanism has never been demonstrated. This fact is logical when one considers that all structurally distinct NSAIDs that inhibit COX-1 can cause respiratory tract reactions in all patients with AERD on first exposure to the new NSAID. Thus drug hapten-antibody recognition cannot be responsible for these reactions.

When patients with AERD undergo aspirin challenges, very substantial increases in uLTE₄ levels and decreases in COX-1 products are recorded during bronchospastic reactions or nasal responses. Increases in LTC₄ and histamine levels in both nasal and bronchial lavage fluid after oral aspirin challenges in patients with AERD, but not aspirin-tolerant control subjects, have also been measured. As shown in Fig 2, during aspirin-induced respiratory reactions, mast cells release histamine and tryptase and synthesize prostanoids (PGD₂) and LTs, and eosinophils secrete toxic molecules and synthesize LTs.
Over the years, it has become clear that excessive synthesis of LTs in patients with AERD undergoing respiratory reactions to NSAIDs or aspirin is secondary to competitive inhibition or disabling of COX-1 enzymes (Fig 2). COX-1 is a constitutively expressed enzyme that is present in most mammalian cells, including respiratory and gastrointestinal epithelial cells, as well as inflammatory cells. COX-2, by contrast, is only expressed in inflammatory cells and is an inducible enzyme that is highly upregulated by proinflammatory mediators, such as cytokines, growth factors, and molecules coming from tissue injury. When COX-1 is inhibited by aspirin and NSAIDs, the braking effects of PGE2 are further reduced or disappear, and 5-LO is unopposed, allowing large increases in synthesis of LTs. Reduced PGE2 synthesis also results in decreased mast cell stability and increased release of histamine and tryptase. During oral aspirin challenges, when patients with AERD were pretreated with inhaled PGE2, they did not experience respiratory reactions, and uLTE4 levels did not increase. The failure of COX-2 inhibitors to cross-react in patients with AERD is further evidence that COX-2 enzymes do not synthesize enough PGE2 to make a difference in the loss of PGE2. This should not be surprising because the small numbers of inflammatory cells synthesizing PGE2, when compared with the millions of cells expressing constitutive COX-1, all epithelial and endothelial cells of the respiratory tract, makes inhibition of COX-2 a minor event from the standpoint of available PGE2. Furthermore, expression of COX-2 is diminished and its activity is reduced in patients with AERD. The fact that meloxicam does not cross-react with aspirin in AERD with low doses (at which COX-2 is inhibited) but does cross-react at high doses (at which COX-1 is inhibited) provides further evidence that COX-1 inhibition is the key event in the induction of aspirin/NSAID-induced respiratory reactions. Finally, the defect of undersynthesizing PGE2 or decreased transcription of EP2 receptors for PGE2 might well render patients with AERD preferentially unable to inhibit 5-LO and FLAP when challenged with aspirin or NSAIDs. This area of research is critical because explaining why inhibition of COX-1 and COX-2 in healthy subjects or aspirin-tolerant asthmatic subjects does not lead to the same respiratory reactions hinges on as-yet-undiscovered fundamental defects unique to patients with AERD.

In addition to increased synthesis of LTs, most patients with AERD also have increased expression of cysLT1 receptors on their inflammatory cells. Thus not only is there an absence of braking effects by PGE2 and a surge of new LT molecules, but the number of cysLT1 receptors on target cells...
are also increased. This tips the equation toward a pronounced increase in end-organ responses to LTs.125

LTs are not the only mediators released or synthesized during aspirin-induced respiratory reactions. Nasal secretions obtained during aspirin-induced reactions contained increased concentrations of histamine, tryptase, LTB4, LTC4, and PGD2 and decreased concentrations of PGE2.117-119,126 The same is true for bronchial secretions during aspirin-lysine–induced lower respiratory tract reactions.75 PGD2 metabolites increase in serum samples during aspirin-induced respiratory reactions.101 During oral aspirin challenges, a minority of patients with AERD have extrapulmonary reactions.54 In such patients histamine and tryptase levels were found to be increased in the systemic circulation.127

Aspirin desensitization (Fig 3)

Aspirin desensitization is one of the most consistent and least understood features of aspirin and asthma. Almost all patients with AERD can be desensitized to aspirin and then take aspirin indefinitely to maintain their desensitized state. During aspirin desensitization, uLTE4 levels returned to baseline,86 and cysLT1 receptor levels decreased significantly.94 At 2 weeks after daily treatment with aspirin, 650 mg twice daily, LTB4 synthesis by peripheral monocytes also decreased significantly in patients with AERD.128 A reduction in synthesis of LTB4 would be therapeutically useful in reducing chemotaxis of eosinophils and polymorphonuclear leukocytes, as well as mast cell progenitors. LTC4 and histamine disappeared in nasal secretions at the onset of aspirin desensitization.117 Biochemically, we can measure specific changes that downregulate inflammation and accompany aspirin desensitization. However, why aspirin desensitization occurs in the first place continues to be a challenging question.

TREATMENT

Avoidance of aspirin and NSAIDs and treatment of reactions

Education of patients regarding complete avoidance of COX-1 inhibitors is important. In particular, asthmatic patients need to be vigilant when ingesting over-the-counter remedies that might include aspirin or NSAIDs (eg, Alka Seltzer Plus Flu, which contains 500 mg of aspirin). In addition, appropriate flagging of charts and communication among health care professionals, including physician and pharmacy computers, is vital in preventing future inappropriate administration of cross-reacting NSAIDs in those patients with AERD already given a diagnosis. We are not advocating universal avoidance of NSAIDs for all asthmatic patients. Such a position denies 80% to 90% of asthmatic subjects access to these important medications. However, use of COX-2 inhibitors, extra care, and thoughtful use of first-dose ingestion of COX-1 inhibitors in physicians’ offices might prevent some inadvertent bronchospastic catastrophes. The major
danger of death from asthma in AERD is the first NSAID-induced reaction, particularly if this occurs far from a medical facility.

Depending on the severity, acute respiratory reactions caused by accidental aspirin or NSAID ingestion are treated with inhaled β-agonists by using multiple dosing (5 inhalations, wait 5 minutes, and then keep repeating inhalation treatments), antihistamines, systemic corticosteroids, and, if systemic histamine release is present, intramuscular epinephrine. Patients who experience laryngospasm respond rapidly to racemic epinephrine administered by means of nebulization. Some patients will need more intense medical attention, including admission to the intensive care unit, intubation, and mechanical ventilation.

Treatment of the underlying respiratory tract disease

Long-term control of both upper and lower airway inflammation is the goal of treatment. High doses of intranasal steroids are helpful in reducing inflammation and retarding nasal polyp formation in some patients. During acute bacterial sinus infections, extended courses of broad-spectrum antibiotics are frequently required. Often patients will also respond to a 2- to 3-week burst of systemic corticosteroids to aid in shrinking nasal polyps and reestablishing temporary sinus drainage. A subset of patients will gradually require continuous systemic corticosteroids. In a review of 300 patients with AERD, systemic corticosteroids were used as short courses in 134 (45%), on a daily basis in 95 (32%), and not at all in 71 (23%). Unfortunately, as daily or frequent bursts of systemic doses of corticosteroids escalate, significant adverse side effects also begin to accumulate.

Zileuton (a 5-LOINH) and montelukast (a cysLT1RA), are commonly used in patients with AERD, with variable success. Dahlen et al131,132 studied the effect of zileuton on the clinical course of 40 patients with AERD in a double-blind placebo-controlled treatment trial and demonstrated efficacy. Montelukast has also been studied in a double-blind placebo-controlled treatment trial in 80 patients with AERD, in which efficacy was also demonstrated.133 CysLT1RA treatment success is distinctly better in the carriers of the variant C allele of LTC4S134-137 and in individuals with the HLA-DPB1*0301 marker.138 In our experience LT-modifier drugs are generally helpful as adjunctive therapy. Particularly in view of the fact that AERD is largely the result of overproduction of cysLTs, the addition of a 5-LOINH or a cysLT1RA to a baseline of topical corticosteroids is now fairly routine treatment for AERD. The use of both zileuton and a cysLT1RA has never been formally studied in patients with AERD but is used by clinicians with anecdotal success.

In patients with AERD who are also atopic, treatment of underlying allergic inflammation should also be maximized. Allergen avoidance, antihistamines, immunotherapy, and anti-IgE treatment should be strongly considered as adjunctive treatment in patients with AERD with this concomitant disorder. It does not make any sense to ignore a concomitant disease, such as allergic rhinitis and asthma, and conclude that AERD by itself is the only important mechanism that is driving eosinophilic inflammation in patients with both AERD and allergic respiratory disease. In a study of 300 patients with AERD, two thirds had positive wheal-and-flare skin test responses to relevant allergens.18

When maximal medical management of nasal polypsis has failed, which is common, referral to a competent otolaryngologist should be initiated. In fact, many patients begin their medical journey with an otolaryngologist because nasal polyposis and anosmia are an early and devastating manifestation of the disease. Nasal polypectomies, resection of eosinophilic inflammatory tissue, and widening of sinus ostia can be performed to help reestablish proper drainage. In addition, at the time of surgery, specimens can be sent for cultures and pathologic investigation, which can be helpful in choosing appropriate antibiotic or antifungal therapy. McFadden et al139 followed 22 patients with AERD who underwent endoscopic sinus surgery for 1 year. Patients showed improvement in pulmonary function testing, need for topical and systemic corticosteroids, and quality-of-life measures. Kennedy140 reported that patients with AERD have the same long-term, postsurgical outcomes as aspirin-tolerant patients, if they have the same degree of mucosal disease. However, patients with AERD as a group tend to have a larger burden of polypoid tissue, and postsurgical regrowth of polypoid tissue remains a significant problem.141 On average, reoperation for nasal polyps is required every 3 years in patients with AERD.18,142

Aspirin desensitization

Aspirin desensitization is an effective yet understaged means of treating patients with AERD. Almost all patients with AERD can be desensitized to aspirin.143 Once desensitized and maintained with daily ingestion of aspirin, patients not only enjoy significant improvement in both upper and lower respiratory symptoms but can also ingest any of the cross-reacting NSAIDs without acute respiratory reactions.144,145 Four long-term studies of patients who underwent aspirin desensitization followed by daily aspirin ingestion have demonstrated efficacy in reducing upper airway congestion and nasal polyp formation and improving lower airway asthma control.142,145-147 One study involved 172 patients desensitized between 1995 and 2000 and treated with aspirin, 650 mg twice daily, for 1 to 5 years.145 Significant reductions in sinus infections and number of rescue oral steroid courses were observed, as well as improvements in anosmia, rhinitis, and asthma symptom scores. Of the 126 patients who completed a year or more of aspirin treatment, 87% experienced good or excellent improvement in their clinical courses. In another study patients began to enjoy improvement in upper airway congestion as early as 4 weeks after starting aspirin treatment.144

Aspirin desensitization should be considered as add-on treatment in patients with uncontrolled upper and lower respiratory symptoms, patients requiring multiple polypectomies and/or sinus operations, patients requiring unacceptably high intermittent or chronic systemic
corticosteroids, and patients requiring aspirin/NSAIDs for treatment of other diseases, such as prophylaxis for coronary artery disease or postoperative stent protection against thrombosis and acute myocardial infarction.

Performing aspirin challenges followed by desensitization is relatively safe. We are not aware of any published or unpublished reports of deaths during controlled oral aspirin challenges. The risk of aspirin-induced asthma can be significantly reduced by using pretreatment with cysLT1RAs. Because the reaction severity is ASA dose dependent, the degree of respiratory reactions is almost always smaller than the original reported aspirin/NSAID-induced reaction with full therapeutic doses of drug.

Chronic aspirin therapy can result in well-known adverse side effects in a minority of patients. In the most recent Scripps Clinic study, 24 (14%) of 172 patients had to discontinue aspirin therapy because of side effects: 14 had epigastric pain, 2 had gastrointestinal bleeding, 2 had bleeding from the nose and ear, and 6 had aspirin-induced urticaria. Patients with a prior history of gastritis, gastrointestinal ulcers, and gastroesophageal reflux might be at higher risk for development of aspirin-induced gastritis, but no prospective study of such patients has been conducted.

CONCLUSION

AERD is a distinct clinical entity that is characterized by aspirin-induced respiratory reactions, asthma, nasal polyposis, and CHES. If not recognized and treated appropriately, AERD has the potential to cause significant morbidity and even mortality, particularly when full doses of aspirin or NSAIDs are ingested away from an acute-care medical facility. Patients must be educated regarding avoidance of aspirin and cross-reacting COX-1 inhibitors to prevent potential life-threatening asthma exacerbations. Treatment of nasal polyp and sinus disease is also essential to effectively control asthma, as well as to significantly prevent secondary respiratory tract infections and improve patients’ quality of life. Aspirin desensitization should be considered as add-on treatment for AERD in many patients. Hopefully, etoricoxib, parecoxib, and lumiracoxib, new selective COX-2 inhibitors available in Europe and elsewhere, will find their way into the US market over the next few years. Further pharmacologic advances, such as a new 5-LO or FLAP inhibitor with improved pharmacokinetics might also be on the horizon.

REFERENCES

80. Elsnor J, Hochestetter R, Kimmel D, Kapp A. Human eosinax repre-

81. Kanoaka Y, Boyce J. Cysteinyl leukotrienes and their receptors: cel-

82. Weller CL, Collington S, Brown KW, Miller HR, Al-Kashi A, Clark P, et al. Leukotriene B4 activation product of mast cells, is a chemoattract-


87. Van Sambeek R, Stevenson DD, Baldasaro M, Lam BK, Zhao J, Yoshida S, et al. 5’ flanking region polymorphism of the gene encoding leukoti-


92. Van Sambeek R, Stevenson DD, Baldasaro M, Lam BK, Zhao J, Yoshida S, et al. 5’ flanking region polymorphism of the gene encoding leukoti-


94. Sousa A, Parikh A, Scadding G, Corrigan CJ, Lee TH. Leukotriene-

95. Powell WS, Rokach J. Biochemistry, biology, chemistry of the 5-lipo-


98. Kunikata T, Yamane H, Segi E, Matsuoka T, Sugimoto Y, Tanaka S, et al. Suppression of allergic inflammation by the prostaglandin E recep-


100. Kowalski ML, Bienkiewicz B, Pawliczak R, DuBuske L. Differential expression of leukotriene C4 synthase in bronchial biop-


102. Van Sambeek R, Stevenson DD, Baldasaro M, Lam BK, Zhao J, Yoshida S, et al. 5’ flanking region polymorphism of the gene encoding leukoti-

103. Powell WS. A novel PGI2 receptor expressed in eosinophils. Prosta-


107. Ying S, Meng Q, Scadding G, Parikh A, Corrigan CJ, Lee TH. Aspirin-
sensitive rhinosinusitis is associated with reduced E-prostanoid 2 recep-


110. Choi JH, Park H, Oh HB, Lee JH, Suh YJ, Park CS, et al. Polymor-
phism of tandem repeat in promoter of 5-lipoxygenase in ASA-intoler-
tant asthma: a positive association with airway hyper responsiveness. Hum Genet 2004;113:337-44.

111. Choi JH, Lee KW, Oh HB, Lee KJ, Suh YJ, Park CS, et al. HLA asso-

112. Dekker JW, Nizankowska E, Schmitz-Schumann M, Pile K, Boheneck G, Dyczek A, et al. Aspirin-induced asthma and HLA-DRB1 and HLA-

113. Kedda MA, Worsley P, Shi J, Phelps S, Duffy D, Thompson PP. Poly-

114. Kim SH, Bae J, Sub CH, Nahm DH, Holloway JW, Park HS. Polymor-
phism of tandem repeat in promoter of 5-lipoxygenase in ASA-intoler-
tant asthma: a positive association with airway hyperresponsiveness. Allergy 2005;60:760-5.

115. Szczeklik A. Adverse reactions to aspirin and nonsteroidal anti-inflam-


